Most Neuroendocrine Tumors Produce Opioid Peptides | Research

The takeaway

All neuroendocrine tumors tested (100%) produced opioid peptides, and even 33-73% of non-neuroendocrine tumors like breast and colon cancer stained positive.

100% of neuroendocrine tumors
Produced opioid peptides detected by pan-opioid antibody

What the researchers found

Using a "pan-opioid" antibody that detects all opioid peptides, researchers screened 108 tumors. Every adrenal pheochromocytoma (15 of 15), thyroid medullary carcinoma (6 of 6), and pituitary adenoma (5 of 5) stained positive for opioid peptides.

Most parathyroid adenomas (8 of 9), pancreatic islet-cell tumors (7 of 10), and carcinoid tumors (18 of 26) also stained positive.

Zero non-neuroendocrine tumors showed opioid staining. Lung small-cell carcinomas, skin Merkel-cell tumors, and neuroblastomas were all negative.

The same opioid peptides were found in normal versions of these tissues (adrenal medulla, pancreatic islets, pituitary), suggesting the tumors simply overproduce a normal cellular product.

Why it matters

This study established opioid peptides as reliable markers for neuroendocrine differentiation in tumors. For pathologists trying to classify unclear tumors, opioid peptide staining could help identify their origin. Published in the New England Journal of Medicine, this was a high-impact finding.

How the study worked

Immunohistochemistry study of 108 tumors using avidin-biotin immunoperoxidase technique. A monoclonal pan-opioid antibody (3-E7) detected the common opioid sequence Tyr-Gly-Gly-Phe. Polyclonal antibodies identified specific opioid subtypes: alpha-endorphin, met-enkephalin, and dynorphin B.

What this study cannot tell us

This was a descriptive study. It did not determine whether opioid peptide production by tumors has any functional consequences (like pain modulation or hormone effects). The sample sizes for individual tumor types were small.

How to read the evidence

Moderate cross-sectional study with a large tumor panel (108) and rigorous immunohistochemistry methodology.

When this study was published

Published in 1987 — established that opioid peptide production by tumors is widespread.

The bigger picture

Tumor-produced opioid peptides could contribute to cancer pain, immune evasion, or tumor growth. This finding opened a research avenue into opioid peptides as cancer biomarkers or therapeutic targets.

Questions still open

Do tumor-derived opioid peptides suppress local immune responses?
Could opioid receptor blockers serve as cancer therapy?
Do opioid peptide levels correlate with tumor aggressiveness?

Common questions

Why would tumors make opioid peptides?

Tumors may use opioid peptides to suppress local immune responses, promote blood vessel growth, or stimulate their own growth. They may also inherit opioid production from their tissue of origin.

Does this explain cancer pain?

Partly. Tumor-produced opioid peptides can bind to pain receptors but their role is complex — they may sometimes suppress and sometimes contribute to pain depending on the specific peptides released.

Read the original research

Expression of opioid peptides in tumors.

The New England journal of medicine, 317(23), 1439-43

View on PubMed ↗

Citation

Bostwick, D G; Null, W E; Holmes, D; Weber, E; Barchas, J D; Bensch, K G. (1987). Expression of opioid peptides in tumors.. The New England journal of medicine, 317(23), 1439-43.